Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study

Abstract

Background: This study investigated real-world patterns of docetaxel use for metastatic castration-resistant prostate cancer (mCRPC) in China. Method(s): A prospective, multi-centre, observational study of Chinese adults (>=18 years) with histologically confirmed metastatic prostate adenocarcinoma who received >=1 dose of docetaxel following hormonal therapy failure (disease progression and serum testosterone <50 ng/dL). The primary endpoint was patterns of docetaxel use. Secondary endpoints included median overall survival (mOS), prostate-specific antigen (PSA) response rate (RR) and reasons for docetaxel discontinuation. Variables are summarised as mean (SD) unless specified. All patients provided written informed consent. Result(s): From August 2011 to June 2016, 403 patients were enrolled at 32 centres and 315 (78.2%) completed the study. The mean number of docetaxel cycles and dose were 4.4 (2.86) and 66.9 mg/m 2 (9.12), and treatment compliance was 94.0% (10.94%). mOS was similar for docetaxel after 1st- or 2nd-line hormonal therapy (Table), and was longer in patients without visceral metastases versus those with visceral metastases (23.3 months vs. 17.4 months, P=0.019). Planned docetaxel treatment was completed by 30.8% (124) of patients; the most common reasons for discontinuation were 'other reasons' (23.3% [94]), cost of medical expenses (22.6% [91]), and tumor progression (14.1% [57]). Treatment-emergent AEs (TEAEs) occurred in 20.8% (84), and serious TEAEs in 4% (16), of patients. Conclusion(s): Around three-quarters of Chinese mCRPC patients treated with docetaxel initiate treatment after failure of 1st- or 2nd-line hormonal therapy and mOS and PSA RR are similar in both settings. Docetaxel was relatively well tolerated. (Table presented).